Navigation Links
Discovery suggests new combination therapy strategy for basal-like breast cancers
Date:5/21/2012

CHAPEL HILL, N.C. Multiple research projects including a 2006 study conducted at the University of North Carolina at Chapel Hill have used DNA microarray analysis to identify several breast cancer subtypes, including luminal A, luminal B, basal-like and HER2-enriched. Simple tests are being developed to help doctors identify these subtypes and to treat their patients in a more biologically-based way. In turn, these tests have made several studies possible that indicate that basal-like, or triple negative breast cancer, is more prevalent in African Americans than their Caucasian counterparts.

A new study led by UNC Lineberger scientist Charles Perou, PhD, and Sean Egan, PhD, from The Hospital for Sick Children in Toronto, Ontario, demonstrates that deletion of a sugar transferase called LFNG (nicknamed "lunatic fringe"), promotes cell proliferation and tumor formation of basal-like breast cancers. The study was published last week in the journal Cancer Cell.

In a laboratory model, the deletion of LFNG not only caused tumors to form but also activated two cellular signaling pathways thought to be important in tumor formation. The team found increased activation of both notch signaling (a receptor found on the surface of cells that is involved in stem cell differentiation and development) and increased expression of the Met oncogene.

Taking the laboratory model a step further, the team examined these same genes and signaling pathways in basal-like tumors and found the same genetic signature.

"This is exciting because there are drugs in development that target each of these pathways. While targeting each pathway alone might work, our findings suggest that combination therapy could be a promising strategy for treating these basal-like tumors," says Dr. Perou, who is the May Goldman Shaw Distinguished Professor of Molecular Oncology and professor of genetics, and pathology and laboratory medicine at the UNC School of Medicine.

Basal-like breast cancer tends to be more aggressive and have a poorer prognosis than other types, making up about 15 percent of all breast cancers. In young African-American women who develop breast cancer, the subtype makes up about 39 percent of all diagnoses. It is primarily treated with chemotherapy, although newer targeted drugs are being tested in clinical trials.


'/>"/>
Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina Health Care
Source:Eurekalert

Related medicine news :

1. Researchers make promising discovery in pursuit of effective lymphoma treatments
2. Scientists make breakthrough in bile duct cancer with discovery of new gene mutations
3. H1N1 discovery paves way for universal flu vaccine: UBC research
4. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
5. Discovery could help to develop drugs for organ transplant and cancer patients
6. Washingtons Life Sciences Discovery Fund awards commercialization grants
7. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
8. New discovery of proteins involved in positioning muscular nuclei
9. Cell signaling discovery provides new hope for blood disorders
10. Gene mutation discovery sparks hope for effective endometriosis screening
11. Discovery predicts patient sensitivity to important drug target in deadly brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology: